Business
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
-- Six abstracts have been accepted for presentation, including updated data on vepdegestrant alone and in combination with palbociclib (IBRANCE®) -- NEW
About this update from Arvinas, Inc.
[{"type":"text","content":"-- Six abstracts have been accepted for presentation, including updated data on vepdegestrant alone and in combination with palbociclib (IBRANCE®) -- NEW HAVEN, Conn. and NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that updated clinical trial data for vepdegestrant (ARV-471) will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS). Vepdegestrant is a novel oral PROteolysis TArgeting Chimera (PROTAC®) estrogen receptor (ER) degrader currently being investigated for the potential treatment of patients with locally advanced or metastatic estrogen receptor (ER) positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer. Arvinas and Pfizer are collaborating to develop and commercialize vepdegestrant. Data from the Phase 1b study assessing vepdegestrant in combination with palbociclib (IBRANCE®) will be presented in a spotlight session on December 7, 2023. An update on the Phase 2 vepdegestrant monotherapy (VERITAC) study will be presented in a poster presentation alongside four other posters during the symposium held from December 5-9, 2023, in San Antonio, Texas. Session details are as follows in chronological order. For more information, visit the official SABCS website here. VERITAC-2 Trial in ProgressPoster Session 1 (ID: PO1-19-12)Wednesday, December 6, 12:00-2:00 PM CTVERITAC-2: a Phase 3 study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER–positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancerMario CamponeVERITAC-3 Study Lead-in Trial in ProgressPoster Session 2 (ID: PO2-20-03)Wednesday, December 6, 5:00-7:00 PM CTVERITAC-3: A randomized Phase 3 study, with a lead-in, of first-line vepdegestrant + palbociclib vs letrozole + palbociclib in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancerSeth WanderTACTIVE-U Trial in ProgressPoster Session 2 (ID: PO2-20-04)Wednesday, December 6, 5:00-7:00 PM CTTACTIVE-U: Phase 1b/2 umbrella study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER–positive advanced or metastatic breast cancerClaudine IsaacsVepdegestrant Monotherapy (VERITAC...